Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.

doi:10.1056/NEJMoa1909512

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.

The New England journal of medicine - 19 Mar 2020

Orkin Chloe, Arasteh Keikawus, Górgolas Hernández-Mora Miguel, Pokrovsky Vadim, Overton Edgar T, Girard Pierre-Marie, Oka Shinichi, Walmsley Sharon, Bettacchi Chris, Brinson Cynthia, Philibert Patrick, Lombaard Johan, St Clair Marty, Crauwels Herta, Ford Susan L, Patel Parul, Chounta Vasiliki, D'Amico Ronald, Vanveggel Simon, Dorey David, Cutrell Amy, Griffith Sandy, Margolis David A, Williams Peter E, Parys Wim, Smith Kimberly Y, Spreen William R

Abstract excerpt

BACKGROUND: Long-acting injectable regimens may simplify therapy for patients with human immunodeficiency virus type 1 (HIV-1) infection. METHODS: We conducted a phase 3, randomized, open-label trial in which adults with HIV-1 infection who had not previously received antiretroviral therapy were given 20 weeks of daily oral induction therapy with dolutegravir-abacavir-lamivudine. Participants who had an HIV-1 RNA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Retroviral Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CD4 Lymphocyte Count

Share to Induction Chemotherapy

Share to Injections, Intramuscular

Share to Maintenance Chemotherapy

Share to Patient Reported Outcome Measures

Share to Pyridones

Share to Rilpivirine

Source

Open in PubMed

Identifiers

PMID: 32130806
DOI: 10.1056/NEJMoa1909512

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.PMID 32130806Read ↗

Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression.Semantic proximity Read ↗

Virological Failure on Long-Acting Injectable Cabotegravir and Rilpivirine: An Analysis of Subtypes, Drug Levels, Resistance, and Therapeutic Implications.Semantic proximity Read ↗

Virological Failure After Switch to Long-Acting Cabotegravir and Rilpivirine Injectable Therapy: An In-depth Analysis.Semantic proximity Read ↗

Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500 000 copies/mL: week 48 outcomes from ACTG 5353.Semantic proximity Read ↗

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.Semantic proximity Read ↗

Genotyping not required for sustained effectiveness of long-acting cabotegravir plus rilpivirine: evidence from the RELATIVITY cohort.Semantic proximity Read ↗

Dolutegravir Monotherapy Versus Dolutegravir/Abacavir/Lamivudine for Virologically Suppressed People Living With Chronic Human Immunodeficiency Virus Infection: The Randomized Noninferiority MONotherapy of TiviCAY Trial.Semantic proximity Read ↗

Efficacy of initial antiretroviral therapy for HIV-1 infection in adults: a systematic review and meta-analysis of 114 studies with up to 144 weeks' follow-up.Semantic proximity Read ↗

Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial.Semantic proximity Read ↗

Raltegravir 1200 mg Once Daily as Maintenance Therapy in Virologically Suppressed HIV-1 Infected Adults : QDISS Open-Label TrialSemantic proximity Read ↗

Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients.Semantic proximity Read ↗

Treatment of Hepatitis C in HIV-Infected Patients: Moving Towards an Era of All Oral Regimens.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.